1. Home
  2. BAX vs ABVX Comparison

BAX vs ABVX Comparison

Compare BAX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baxter International Inc.

BAX

Baxter International Inc.

HOLD

Current Price

$19.61

Market Cap

9.4B

Sector

Health Care

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$117.49

Market Cap

9.6B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAX
ABVX
Founded
1931
2013
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
9.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BAX
ABVX
Price
$19.61
$117.49
Analyst Decision
Hold
Strong Buy
Analyst Count
10
12
Target Price
$25.67
$112.83
AVG Volume (30 Days)
8.2M
1.7M
Earning Date
10-30-2025
08-11-2025
Dividend Yield
0.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,023,000,000.00
$7,073,400.00
Revenue This Year
$5.20
$6.80
Revenue Next Year
$2.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.90
N/A
52 Week Low
$17.40
$4.77
52 Week High
$37.74
$138.49

Technical Indicators

Market Signals
Indicator
BAX
ABVX
Relative Strength Index (RSI) 57.40 53.15
Support Level $17.92 $107.06
Resistance Level $19.17 $138.49
Average True Range (ATR) 0.47 7.25
MACD 0.23 -0.35
Stochastic Oscillator 89.47 37.95

Price Performance

Historical Comparison
BAX
ABVX

About BAX Baxter International Inc.

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: